Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing

被引：138

作者：

Placencio, Veronica R. ^{[1
,2
]}

DeClerck, Yves A. ^{[1
,2
,3
]}

机构：

[1] Univ So Calif, Dept Pediat, Div Hematol Oncol & Blood & Bone Marrow Transplan, Los Angeles, CA 90089 USA

[2] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA

[3] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA

来源：

CANCER RESEARCH | 2015年 / 75卷 / 15期

基金：

美国国家卫生研究院;

关键词：

FIBROSARCOMA CELLS; PAI-1; INHIBITOR; BREAST-CANCER; TUMOR-GROWTH; WILD-TYPE; UROKINASE; TYPE-1; ANGIOGENESIS; DEFICIENT; BINDING;

D O I：

10.1158/0008-5472.CAN-15-0876

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents. (C) 2015 AACR.

引用

页码：2969 / 2974

页数：6

共 50 条

[31] Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer
Pierga, JY
LaineBidron, C
Beuzeboc, P
DeCremoux, P
Pouillart, P
Magdelenat, H
[J]. BRITISH JOURNAL OF CANCER, 1997, 76 (04) : 537 - 540
[32] The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
Villadsen, S. B.
Bramsen, J. B.
Ostenfeld, M. S.
Wiklund, E. D.
Fristrup, N.
Gao, S.
Hansen, T. B.
Jensen, T. I.
Borre, M.
Orntoft, T. F.
Dyrskjot, L.
Kjems, J.
[J]. BRITISH JOURNAL OF CANCER, 2012, 106 (02) : 366 - 374
[33] Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling
Stefansson, S
McMahon, GA
Petitclerc, E
Lawrence, DA
[J]. CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (19) : 1545 - 1564
[34] Research Progress in Tumor Therapy Targeting Plasminogen Activator Inhibitor-1
Liu Ji-Hao
Tang Shu-Zhi
Hu Li-Hong
Huang Ming-Dong
Chen Zhuo
[J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2019, 46 (07) : 663 - 672
[35] Three Decades of Research on Plasminogen Activator Inhibitor-1: A Multifaceted Serpin
Declerck, Paul J.
Gils, Ann
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (04) : 356 - 364
[36] Modulation of plasminogen activator inhibitor-1 (PAI-1) by the naphthoquinone shikonin
Han, Tingting
Zhang, Guangping
Yan, Dong
Yang, Hong
Ma, Tonghui
Ye, Zuguang
[J]. FITOTERAPIA, 2016, 113 : 117 - 122
[37] The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer
Meo, S
Dittadi, R
Peloso, L
Gion, M
[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (04) : 282 - 288
[38] Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility
Oh, Jisu
An, Hui Jeong
Kim, Jung Oh
Jun, Hak Hoon
Kim, Woo Ram
Kim, Eo Jin
Oh, Doyeun
Kim, Jong Woo
Kim, Nam Keun
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 15
[39] Prognostic Impact of Plasminogen Activator Inhibitor Type 1 Expression in Bladder Cancer
Becker, Markus
Szarvas, Tibor
Wittschier, Markus
vom Dorp, Frank
Toetsch, Martin
Schmid, Kurt Werner
Ruebben, Herbert
Erguen, Sueleyman
[J]. CANCER, 2010, 116 (19) : 4502 - 4512
[40] Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer
Chen, Shutong
Tai, Haifeng
Tong, Xiaowen
Wang, Jianjun
Yang, Fang
Yang, Yang
Ouyang Yiqin
[J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2014, 40 (09) : 2058 - 2065

← 1 2 3 4 5 →